National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Chronic Myeloproliferative Disorders Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 08/01/2008



General Information About Chronic Myeloproliferative Disorders






Chronic Myelogenous Leukemia






Polycythemia Vera






Chronic Idiopathic Myelofibrosis






Essential Thrombocythemia






Chronic Neutrophilic Leukemia






Chronic Eosinophilic Leukemia






Stages of Chronic Myeloproliferative Disorders






Treatment Option Overview






Treatment Options for Chronic Myeloproliferative Disorders






To Learn More About Chronic Myeloproliferative Disorders






Get More Information From NCI






Changes to This Summary (08/01/2008)






About PDQ



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Essential Thrombocythemia

Key Points for This Section


Essential thrombocythemia is a disease in which too many platelets are made in the bone marrow.

Essential thrombocythemia causes an abnormal increase in the number of platelets made in the blood and bone marrow.

Patients with essential thrombocythemia may have no symptoms.

Essential thrombocythemia often does not cause early symptoms. It is sometimes found during a routine blood test. The following symptoms may be caused by essential thrombocytopenia or by other conditions. A doctor should be consulted if any of these problems occur:

  • Headache.
  • Burning or tingling in the hands or feet.
  • Redness and warmth of the hands or feet.
  • Vision or hearing problems.

Platelets are sticky. When there are too many platelets, they may clump together and make it hard for the blood to flow. Clots may form in blood vessels and there may also be increased bleeding. These can cause serious health problems such as stroke or heart attack.

Certain factors affect prognosis (chance of recovery) and treatment options for essential thrombocythemia.

Prognosis (chance of recovery) and treatment options depend on the following:

  • The age of the patient.
  • Whether the patient has symptoms or other problems related to essential thrombocythemia.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov